Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Condition(s):POMES Syndrome; Relapsed and Refractory POMES SyndromeLast Updated:August 6, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):POMES Syndrome; Relapsed and Refractory POMES SyndromeLast Updated:August 6, 2021Unknown status
Condition(s):Peripheral T Cell LymphomaLast Updated:August 10, 2022Recruiting
Condition(s):Multiple MyelomaLast Updated:January 30, 2024Active, not recruiting
Condition(s):LymphomaLast Updated:April 11, 2018Recruiting
Condition(s):Pediatric Solid TumorLast Updated:August 21, 2023Recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:October 12, 2022Not yet recruiting
Condition(s):Leukemia, Myelogenous, Acute; Myelodysplastic SyndromesLast Updated:August 8, 2017Terminated
Condition(s):Mantle Cell LymphomaLast Updated:March 22, 2024Not yet recruiting
Condition(s):Multiple MyelomaLast Updated:February 15, 2024Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:May 31, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.